Conservative management of young patients with endometrial highly-differentiated adenocarcinoma

References

• Agorastos T, Bontis J, Vakiani A, Vavilis D, Constantinidis T. 1997. Treatment of endometrial hyperplasia with gonadotropin-releasing hormone agonists: pathologic, clinical, morphometric and DNA-cytometric data. Gynecologic Oncology 65:102–114.
   PubMedGoogle Scholar
• Agorastos T, Vaitsi V, Paschopoulos M, Vakiani A, Zournatzi-Koiou B, Saravelos H, et al. 2004. Use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia. Maturitas 48:125–132.
   PubMed Web of Science ®Google Scholar
• Agorastos T, Vaitsi V, Pantazis K, Efstathiadis E, Vavilis D, Bontis JN. 2005. Aromatase inhibitor anastrazile for treating endometrial hyperplasia in obese postmenopausal women. European Journal of Obstetrics, Gynecology, and Reproductive Biology 118:239–240.
   PubMed Web of Science ®Google Scholar
• Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. 2005. Endometrial cancer. Lancet 366:491–505.
   PubMed Web of Science ®Google Scholar
• Ball HG. 1996. Do we know the best therapy for the early stage endometrial cancer? Gynecologic Oncology 60:173–175.
   PubMedGoogle Scholar
• Bozdag G. 2009. ICSI outcome following conservative fertility sparing management of endometrial cancer. RBM Online 18:416–420.
   Google Scholar
• Chiva L, Lapuente F, Gonzalez-Cortijo L, Garballo L, Garcia JF, Rojo A, et al. 2008. Sparing fertility in young patients with endometrial cancer. Gynecologic Oncology 111:S101–S104.
   Google Scholar
• Covens A, Thomas G, Shaw P. 1997. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecologic Oncology 64:126–129.
   PubMed Web of Science ®Google Scholar
• Crissman JD, Azoury RS, Barnes AE, Schellhas HF. 1981. Endometrial carcinoma in women 40 years of age or younger. Obstetrics and Gynecology 57:699–704.
   PubMed Web of Science ®Google Scholar
• Eftekhar Z, Izadi-Mood N, Yarandi F, Shojaei H, Rezaei Z, Mohagheghi S. 2009. Efficacy of megestrol acetate (Megace) in the treatment of patients with early endometrial adenocarcinoma: our experience with 21 patients. International Journal of Gynecological Cancer 19:249–252.
   PubMed Web of Science ®Google Scholar
• Elizur SE, Beiner ME, Korach J, Weiser A, Ben-Baruch G, Dor J. 2007. Outcome of in vitro fertilization treatment in infertile women conservatively treated for endometrial adenocarcinoma. Fertility and Sterility 88:1562–1567.
   PubMedGoogle Scholar
• Evans-Metcalf ER, Brooks SE, Reale FR, Baker SP. 1998. Profile of women 45 years of age and younger with endometrial cancer. Obstetrics and Gynecology 91:349–354.
   PubMed Web of Science ®Google Scholar
• Ferenczy A, Gelfand M. 1989. The biologic significance of cytologic atypia in progesterone-treated endometrial hyperplasia. American Journal of Obstetrics and Gynecology 160:126–131.
   PubMed Web of Science ®Google Scholar
• Gal D, Edman CD, Vellios F, Forney JP. 1983. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia. American Journal of Obstetrics and Gynecology 146:316–321.
   PubMedGoogle Scholar
• Gallup DG, Stock RJ. 1984. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstetrics and Gynecology 64:417–420.
   PubMed Web of Science ®Google Scholar
• Gatta G, Lasota MB, Verfecchia A, and the EUROCARE Working Group. 1998. Survival of European Women with Gynaecological Tumours During the Period 1978–1989. European Journal of Cancer 34:2218–2225.
   PubMed Web of Science ®Google Scholar
• Guven M, Dikmen Y, Terek MC, Ozsaran AA, Itil IM, Erhan Y. 2001. Metabolic effect associated with high- dose continuous megestrol acetate administration in the treatment of endometrial pathology. Archives of Gynecology and Obstetrics 265:183–186.
   PubMedGoogle Scholar
• Han AR, Kwon YS, Kim DY, Kim JH, Kim YM, Kim YT, et al. 2009. Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia. International Journal of Gynecological Cancer 19:147–151.
   PubMedGoogle Scholar
• Howell A, Cuzick J. 2005. Vascular effects of aromatase inhibitors: data from clinical trials. Journal of Steroid Biochemistry and Molecular Biology 95:143–149.
   PubMed Web of Science ®Google Scholar
• Janicek MF, Rosenheim NB. 1994. Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia. Gynecologic Oncology 52:373–378.
   PubMed Web of Science ®Google Scholar
• Janni W, Hepp P. 2010. Adjuvant aromatase inhibitor therapy: Outcomes and safety. Cancer Treatment Reviews 36:249–261.
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun NJ. 2003. Cancer statistics. CA: A Cancer Journal for Clinicians 53:5–26.
   PubMed Web of Science ®Google Scholar
• Kalogiannidis I, Lambrechts S, Amant F, Neven P, Van Gorp T, Vergote Ig. 2007. Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence and long term outcomes. American Journal of Obstetrics and Gynecology 196:248.e1–e8.
   PubMedGoogle Scholar
• King A, Seraj IM, Wagner RJ. 1984. Stromal invasion in endometrial carcinoma. American Journal of Obstetrics and Gynecology 149:10–14.
   PubMedGoogle Scholar
• Kistner RW. 1959. Histological effect of progestin on hyperplasia and carcinoma in situ of the endometrium. Cancer 12:1106.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Norris HJ. 1982. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer 49:2547–2559.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Kaminski PF, Norris HJ. 1985. The behavior of endometrial hyperplasia. A long-term study of ‘untreated’ hyperplasia in 170 patients. Cancer 56:403–412.
   PubMed Web of Science ®Google Scholar
• Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. 2002. Intrauterine progesterone treatment of early endometrial cancer. American Journal of Obstetrics and Gynecology 186:651–657.
   PubMed Web of Science ®Google Scholar
• Niwa K, Tagami K, Lian Z. 2005. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. British Journal of Obstetrics and Gynaecology 112:317–320.
   Google Scholar
• Ota T, Yoshida M, Kimura M, Kinishita K. 2005. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. International Journal of Gynecological Cancer 15:657–662.
   PubMed Web of Science ®Google Scholar
• Perez-Medina T, Bajo J, Folgueira G, Haya J, Ortega P. 1999. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormones analogues: long-term follow-up. Gynecologic Oncology 73:299–304.
   PubMed Web of Science ®Google Scholar
• Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. 2004. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecologic Oncology 95:133–138.
   PubMed Web of Science ®Google Scholar
• Randall TC, Kurman RJ. 1997. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under the age 40. Obstetrics and Gynecology 90:434–440.
   PubMed Web of Science ®Google Scholar
• Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, Allison K, et al. 2009. Incidence of endometrial hyperplasia. American Journal of Obstetrics and Gynecology 200:678.e1–e6.
   PubMed Web of Science ®Google Scholar
• Ronnett BM, Kurman RJ. 2002. Precursor lesions of endometrial carcinoma. Blaustein's pathology of the female genital tract. In: Kurman RJ, editor. 5th ed. New York: Springer-Verlag; p 467–500.
   Google Scholar
• Shapiro CL. 2005. Aromatase Inhibitors and bone loss: risk in perspective. Journal of Clinical Oncology 23:4847–4849.
   PubMedGoogle Scholar
• Signorelli M, Caspani G, Bonazzi C, Chiappa V, Perego P, Mangioni C. 2009. Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. British Journal of Obstetrics and Gynaecology 116:114–118.
   Google Scholar
• Sodano M. 2009. Successful IVF programme after conservatively treated endometrial cancer. RBM Online 18:578–581.
   Google Scholar
• Surrey ES. 2010. Gonadotropin-releasing hormone agonist and add-back therapy what do the data show? Current Opinion in Obstetrics and Gynecology 22:283–288.
   PubMed Web of Science ®Google Scholar
• Tamaoka Y, Orikasa H, Sumi Y, Sakakura K, Kamei K, Nagatani M, et al. 2004. Treatment of endometrial hyperplasia with a danazol-releasing intrauterine device: a prospective study. Gynecologic and Obstetric Investigation 58:42–48.
   PubMedGoogle Scholar
• Ushijima K, Yahata H, Yoshikawa H, Konisi I, Yasugi T, Saito T, et al. 2007. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. Journal of Clinical Oncology 25:2798–2803.
   PubMed Web of Science ®Google Scholar
• Varga A, Henriksen E. 1961. Clinical and histopathologic evaluation of the effect of 17-alpha-hydroxyprogesterone-17-n-caproate on endometrial carcinoma. Obstetrics and Gynecology 18:658–672.
   PubMed Web of Science ®Google Scholar
• Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al. 2008. The effectiveness of levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia- A long-term follow-up study. European Journal of Obstetrics, Gynecology, and Reproductive Biology 139:169–175.
   PubMed Web of Science ®Google Scholar
• Widra EA, Dunton CJ, McHugh M, Palazzo JP. 1995. Endometrial hyperplasia and the risk for carcinoma. International Journal of Gynecological Cancer 5:233–235.
   PubMedGoogle Scholar
• Yamazawa K, Hirai M, Fujito A, Nishi H, Terauchi F, Ishikura H, et al. 2007. Fertility-preserving treatment with progestin and pathological criteria to predict responses, in young women with endometrial cancer. Human Reproduction 22:1953–1958.
   PubMed Web of Science ®Google Scholar
• Yang YC, Wu CC, Chen CP, Chang CL, Wang KL. 2005. Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer. Gynecologic Oncology 99:287–293.
   PubMedGoogle Scholar